U.S. Public Health Service Lieutenant Commander Emeka Egwim left his position as director of OPA at HRSA 21 months after he started.
U.S. Public Health Service Lieutenant Commander Emeka Egwim left his position as director of the federal office overseeing the 340B [...] …
The House E&C Committee on Dec. 6 unanimously approved a PBM transparency bill with a 340B program provision.
Lawmakers on a key House committee approved a pharmacy benefit manager (PBM) transparency bill on Wednesday that would require PBMs [...] …
SPONSORED CONTENT The 340B program serves as a lifeline for many communities, allowing them to provide critical services to vulnerable, [...] …
The final HRSA manufacturer 340B program audit conducted in fiscal year 2023 had no adverse findings for Teva Pharmaceuticals.
The fifth and final fiscal year 2023 manufacturer audit by federal officials recently concluded with no adverse findings. Meanwhile, the [...] …
Sen. Mike Crapo (R-Idaho), ranking member of the Senate Finance Committee, said penny pricing under 340B warranted “serious scrutiny in the context of generic products.”
Two Republican Senators on an influential committee suggested during a hearing on Tuesday that 340B discounts could contribute to certain [...] …
In response to the ongoing Change Healthcare cyberattack, CMS will direct contractors to provide some accelerated payments to hospitals.
Critical access hospitals (CAHs) and Ryan White HIV/AIDS clinics do not expect problems implementing a new requirement starting Jan. 1, [...] …
Federal auditors determined terminations from the 340B program were required for either covered entity sites or a contract pharmacy of two more 340B providers.
Federal auditors determined terminations from the 340B program were required for either covered entity sites or contract pharmacies of four [...] …
Drugmaker Biogen recently added a third drug to its 340B contract pharmacy restrictions for hospitals.
Biopharmaceutical manufacturer Biogen recently expanded its contract pharmacy restrictions for hospitals to a third drug, after that medication garnered a [...] …
*Sign up for news summaries and alerts from 340B Report
Copyright © 2025 340B Report, LLC
Reproduction of material from any 340B Report page without written permission is strictly prohibited.
